Lynparza Breast Cancer Clinical Experience Investigation

AstraZeneca111 enrolled

Overview

To characterise the development of ADRs of bone marrow depression in patients under actual post-marketing use

To characterise the development of adverse drug reactions (ADRs) of bone marrow depression in patients with unresectable or recurrent BRCA mutated HER2 negative breast cancer who have previously received anticancer chemotherapy under actual post-marketing use.

Study Type

OBSERVATIONAL

Enrollment

111

Conditions

Breast Cancer

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Unresectable or recurrent BRCA mutated HER2 negative breast cancer with prior anticancer chemotherapy Exclusion Criteria: * The patients who are not started on Lymparza for the first time

Locations (31)

Research Site

Aichi, Japan

Outcomes

Primary Outcomes

Adverse drug reactions of bone marrow depression

Bone marrow depression will be investigated as safety specification topics

Time frame: One year period

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.